JP2017529398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529398A5 JP2017529398A5 JP2017535141A JP2017535141A JP2017529398A5 JP 2017529398 A5 JP2017529398 A5 JP 2017529398A5 JP 2017535141 A JP2017535141 A JP 2017535141A JP 2017535141 A JP2017535141 A JP 2017535141A JP 2017529398 A5 JP2017529398 A5 JP 2017529398A5
- Authority
- JP
- Japan
- Prior art keywords
- pyocin
- therapeutic composition
- type
- subject
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025955 Pyocins Proteins 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 230000002685 pulmonary effect Effects 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 2
- 230000008371 airway function Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000036737 immune function Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1416788.6 | 2014-09-23 | ||
| GBGB1416788.6A GB201416788D0 (en) | 2014-09-23 | 2014-09-23 | Therapeutic applications for pyocins |
| PCT/EP2015/071768 WO2016046218A1 (en) | 2014-09-23 | 2015-09-22 | Pulmonary administration of pyocins for treating bacterial respiratory infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529398A JP2017529398A (ja) | 2017-10-05 |
| JP2017529398A5 true JP2017529398A5 (enExample) | 2018-10-25 |
| JP6836506B2 JP6836506B2 (ja) | 2021-03-03 |
Family
ID=51869352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535141A Active JP6836506B2 (ja) | 2014-09-23 | 2015-09-22 | 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11643442B2 (enExample) |
| EP (1) | EP3200813B1 (enExample) |
| JP (1) | JP6836506B2 (enExample) |
| CN (1) | CN107073073B (enExample) |
| CA (1) | CA2962117C (enExample) |
| GB (1) | GB201416788D0 (enExample) |
| WO (1) | WO2016046218A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111770687A (zh) * | 2017-12-14 | 2020-10-13 | 拜克多科利尔私人控股有限公司 | 治疗性细菌素 |
| US20220024992A1 (en) * | 2018-11-02 | 2022-01-27 | The Rockefeller University | Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria |
| WO2020104397A1 (en) * | 2018-11-19 | 2020-05-28 | Bioaster | Methods and reagents for multiplex binding experiments |
| AU2020287918A1 (en) * | 2019-06-06 | 2021-12-16 | Nomad Bioscience Gmbh | Klebicins for the control of Klebsiella |
| EP4248987A1 (en) * | 2022-03-21 | 2023-09-27 | Nomad Bioscience GmbH | Chimeric bacteriocins and method for the control of pseudomonas |
| CN121135836A (zh) * | 2024-06-14 | 2025-12-16 | 无锡佰翱得生物科学股份有限公司 | 一种绿脓杆菌免疫蛋白及其应用 |
| CN121135834A (zh) * | 2024-06-14 | 2025-12-16 | 无锡佰翱得生物科学股份有限公司 | 一种绿脓杆菌InA蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861754A (en) | 1986-05-28 | 1989-08-29 | Farkas Himsley Hannah | Bacteriocins and compositions thereof in anti-viral treatment |
| JP3655645B2 (ja) * | 1992-02-28 | 2005-06-02 | 中外製薬株式会社 | 経粘膜投与剤 |
| WO1998020836A2 (en) | 1996-11-15 | 1998-05-22 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| AU7572900A (en) * | 1999-08-26 | 2001-03-19 | Vion Pharmaceuticals, Inc. | Compositions and methods for delivery of an agent using attenuated salmonella containing phage |
| US20060229244A1 (en) * | 2004-09-27 | 2006-10-12 | Robert Dorit | Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections |
| US7700729B2 (en) * | 2006-05-15 | 2010-04-20 | Avidbiotics Corporation | Modified bacteriocins and methods for their use |
| CA2652450C (en) * | 2006-05-15 | 2013-10-15 | Avidbiotics Corporation | Modified bacteriocins and methods for their use |
| US20110129438A1 (en) * | 2006-06-28 | 2011-06-02 | James Robert Swartz | Immunogenic protein constructs |
| US20080286236A1 (en) * | 2007-05-14 | 2008-11-20 | Avidbiotics Corporation | Inhibition of yersinia pestis |
| WO2012140676A2 (en) * | 2011-04-12 | 2012-10-18 | Appaiah C B | Chimeric antibacterial polypeptides |
| GB201116234D0 (en) * | 2011-09-20 | 2011-11-02 | Aseptika Ltd | Biomarkers for respiratory infection |
-
2014
- 2014-09-23 GB GBGB1416788.6A patent/GB201416788D0/en not_active Ceased
-
2015
- 2015-09-22 EP EP15767472.2A patent/EP3200813B1/en active Active
- 2015-09-22 US US15/512,548 patent/US11643442B2/en active Active
- 2015-09-22 JP JP2017535141A patent/JP6836506B2/ja active Active
- 2015-09-22 CN CN201580057704.5A patent/CN107073073B/zh active Active
- 2015-09-22 WO PCT/EP2015/071768 patent/WO2016046218A1/en not_active Ceased
- 2015-09-22 CA CA2962117A patent/CA2962117C/en active Active
-
2023
- 2023-02-23 US US18/173,333 patent/US12162911B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Waters et al. | Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa | |
| JP2015517489A5 (enExample) | ||
| Edwards et al. | The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations | |
| CN115605510A (zh) | B7h3抗体-依喜替康类似物偶联物及其医药用途 | |
| PH12018500088A1 (en) | Substituted tricyclics and method of use | |
| JP2018523668A5 (enExample) | ||
| JP2020537659A5 (enExample) | ||
| JP2016509011A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2004533246A5 (enExample) | ||
| ZA202201828B (en) | Therapeutic fusion proteins | |
| JP2016513688A5 (enExample) | ||
| Gill et al. | Delivery of genes into the CF airway | |
| JP6836506B2 (ja) | 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 | |
| MX377175B (es) | Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc). | |
| JP2012525346A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2019531293A5 (enExample) | ||
| JP2017527618A5 (enExample) | ||
| van der Ploeg | The dilemma of two innovative therapies for spinal muscular atrophy | |
| HK1251998A1 (zh) | 佐米曲普坦肺部给药粉 | |
| Ehrmann et al. | Aerosolized antibiotic therapy in mechanically ventilated patients | |
| Chen et al. | Pulmonary empyema caused by co-infections of Mycoplasma pneumoniae and Fusobacterium necrophorum: a rare case of lemierre syndrome | |
| WO2021205026A3 (en) | Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. |